State of the art therapy for metastatic breast cancer

Edith A. Ferez

Research output: Contribution to journalReview article


Although definite curative therapy for metastatic breast cancer is lacking, a variety of therapies are used in an attempt to retard the progression of disease, ameliorate symptoms, and improve the quality and duration of survival time. In addition to the well-defined improvements in the supportive care of patients with metastatic breast cancer, a variety of new therapeutic agents with favorable therapeutic ratios have recently become available. These agents include hormonal, chemotherapeutic, and monoclonal antibody therapies. How best to incorporate these new strategies into the current management of patients is currently the focus of intensive preclinical and clinic research. Several recently completed and ongoing clinical trials promise to define the role of these new treatments in the management of metastatic breast cancer.

Original languageEnglish (US)
Pages (from-to)289-295
Number of pages7
JournalCancer Research Therapy and Control
Issue number3-4
StatePublished - Sep 29 1999


  • Chemotherapy
  • Hormonal therapy
  • Monoclonal antibody

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'State of the art therapy for metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this